{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:31:15Z","timestamp":1792132275767,"version":"4.4.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The emergence and subsequent spread of antimalarial drug resistance represent a significant threat to the efficacy of artemisinin-based combination therapies (ACTs) in sub-Saharan Africa. Multiple molecular markers have been implicated in resistance to artemisinin and its partner drugs. We conducted a systematic review and meta-analysis of studies published between 2010 and 2024 in sub-Saharan Africa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The protocol was registered in PROSPERO (CRD42023432718). Studies were identified through PubMed\/MEDLINE, Web of Science, Scopus, Embase, and African Journal Online. Study selection, data extraction, and risk-of-bias assessment were performed independently by two reviewers in accordance with the PRISMA 2020 guidelines. Prevalence data for mutations in\n                      <jats:italic>PfKelch13<\/jats:italic>\n                      ,\n                      <jats:italic>Pfcrt<\/jats:italic>\n                      ,\n                      <jats:italic>Pfmdr1<\/jats:italic>\n                      , and\n                      <jats:italic>Pfdhfr\/Pfdhps<\/jats:italic>\n                      were extracted and analysed using random-effects models, with pooled prevalence estimates generated using a generalized linear mixed model (GLMM) with logit transformation. Between-study heterogeneity was assessed using Cochran\u2019s Q and I\n                      <jats:sup>2<\/jats:sup>\n                      statistics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 172 studies on\n                      <jats:italic>PfKelch13<\/jats:italic>\n                      , 182 on\n                      <jats:italic>Pfcrt<\/jats:italic>\n                      , 196 on\n                      <jats:italic>Pfmdr1<\/jats:italic>\n                      , and 176 on\n                      <jats:italic>Pfdhfr\/Pfdhps<\/jats:italic>\n                      were included. From 2014 to 2023, validated\n                      <jats:italic>PfKelch13<\/jats:italic>\n                      mutations exhibited marked spatial and temporal heterogeneity, with R622I, R561H, and A675V expanding primarily in East Africa, reaching prevalences of 10\u201325% in Rwanda, Uganda, and Tanzania. In Central Africa, emergence was observed in 2021 at low levels (below 5%), while West Africa reported only sporadic low-prevalence (below 1%) detections. In contrast, resistance to some partner drugs declined substantially across Africa, with\n                      <jats:italic>Pfcrt<\/jats:italic>\n                      K76T decreasing from 76% (95% CI: 49% \u2212 91%;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u2009=\u200997.9%) in 2010 to 9% (95% CI: 8.7% \u2212 9.5%;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u2009=\u200996.8%) in 2023 and\n                      <jats:italic>Pfmdr1<\/jats:italic>\n                      N86Y falling from 34% (95% CI: 26% \u2212 43%;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u2009=\u200993.5%) to zero (95% CI: 0% \u2212 11%;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u2009=\u200997.1%), with persistent regional heterogeneity. Certain markers of sulfadoxine\u2013pyrimethamine (SP) resistance (\n                      <jats:italic>Pfdhfr<\/jats:italic>\n                      N51I, C59R, S108N and\n                      <jats:italic>Pfdhps<\/jats:italic>\n                      A437G) remained near fixation, whereas\n                      <jats:italic>Pfdhfr<\/jats:italic>\n                      I164L,\n                      <jats:italic>Pfdhps<\/jats:italic>\n                      K540E, and\n                      <jats:italic>Pfdhps<\/jats:italic>\n                      A581G showed pronounced spatial clustering, with the highest prevalence reported in East and parts of Central Africa.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, the temporal and regional patterns of antimalarial drug resistance molecular markers across sub-Saharan Africa underscore the need for sustained molecular surveillance tailored to local epidemiological trends of resistance markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>Protocol registered in the International Prospective Register of Systematic Reviews (PROSPERO; registration number CRD42023432718).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-14233-2","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:44:06Z","timestamp":1788443046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Spatio-temporal trends of the prevalence of Plasmodium falciparum antimalarial drug resistance markers across sub-Saharan Africa from 2010 to 2024: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Francis Emmanuel","family":"Towanou Bohissou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu\u00e9tawend\u00e9 Job","family":"Wilfried Nassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toussaint","family":"Rouamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Yessinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halidou","family":"Tinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"14233_CR1","unstructured":"World malaria report. 2025 n.d. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2025 (accessed February 2, 2026)."},{"key":"14233_CR2","unstructured":"World malaria report. 2024 n.d. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024 (accessed March 12, 2025)."},{"issue":"1","key":"14233_CR3","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1186\/s12879-025-12130-8","volume":"25","author":"FET Bohissou","year":"2025","unstructured":"Bohissou FET, Nassa GJW, Sondo P, Rouamba T, Inoue J, Kabor\u00e9 B, et al. Spatio-temporal trends of artemisinin-based combination therapy efficacy from 2010 to 2024 in sub-saharan Africa: a systematic review and meta-analysis. BMC Infect Dis. 2025;25(1):1684. https:\/\/doi.org\/10.1186\/s12879-025-12130-8.","journal-title":"BMC Infect Dis"},{"key":"14233_CR4","doi-asserted-by":"publisher","unstructured":"Marwa K, Kapesa A, Baraka V, Konje E, Kidenya B, Mukonzo J, et al. Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa: a systematic review and meta-analysis. PLoS ONE. 2022;17(3):e0264339. https:\/\/doi.org\/10.1371\/journal.pone.0264339.","DOI":"10.1371\/journal.pone.0264339"},{"issue":"6","key":"14233_CR5","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S1473-3099(21)00692-7","volume":"22","author":"TJ Peto","year":"2022","unstructured":"Peto TJ, Tripura R, Callery JJ, Lek D, Nghia HDT, Nguon C, et al. Triple therapy with artemether\u2013lumefantrine plus amodiaquine versus artemether\u2013lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. The Lancet Infect Dis. 2022;22(6):867\u201378. https:\/\/doi.org\/10.1016\/S1473-3099(21)00692-7.","journal-title":"The Lancet Infect Dis"},{"key":"14233_CR6","unstructured":"Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010-2019) n.d. https:\/\/www.who.int\/publications-detail-redirect\/9789240012813. accessed March 15, 2023."},{"issue":"24","key":"14233_CR7","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc0805011","volume":"359","author":"H Noedl","year":"2008","unstructured":"Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359(24):2619\u201320. https:\/\/doi.org\/10.1056\/NEJMc0805011.","journal-title":"N Engl J Med"},{"issue":"4","key":"14233_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1473-3099(15)70032-0","volume":"15","author":"KM Tun","year":"2015","unstructured":"Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. The Lancet Infect Dis. 2015;15(4):415\u201321. https:\/\/doi.org\/10.1016\/S1473-3099(15)70032-0.","journal-title":"The Lancet Infect Dis"},{"issue":"1","key":"14233_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12942-016-0064-6","volume":"15","author":"EPM Grist","year":"2016","unstructured":"Grist EPM, Flegg JA, Humphreys G, Mas IS, Anderson TJC, Ashley EA, et al. Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia. Int J Health Geogr. 2016;15(1):37. https:\/\/doi.org\/10.1186\/s12942-016-0064-6.","journal-title":"Int J Health Geogr"},{"issue":"9","key":"14233_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/tropicalmed9090223","volume":"9","author":"D Zheng","year":"2024","unstructured":"Zheng D, Liu T, Yu S, Liu Z, Wang J, Wang Y. Antimalarial mechanisms and resistance status of artemisinin and its derivatives. Trop Med Infect Dis. 2024;9(9):223. https:\/\/doi.org\/10.3390\/tropicalmed9090223.","journal-title":"Trop Med Infect Dis"},{"issue":"1","key":"14233_CR11","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41467-020-20805-w","volume":"12","author":"S Mok","year":"2021","unstructured":"Mok S, Stokes BH, Gn\u00e4dig NF, Ross LS, Yeo T, Amaratunga C, et al. Artemisinin-resistant K13 mutations rewire Plasmodium falciparum\u2019s intra-erythrocytic metabolic program to enhance survival. Nat Commun. 2021;12(1):530. https:\/\/doi.org\/10.1038\/s41467-020-20805-w.","journal-title":"Nat Commun"},{"key":"14233_CR12","unstructured":"Malaria: Artemisinin partial resistance n.d. https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/artemisinin-resistance. accessed December 1, 2025."},{"issue":"10","key":"14233_CR13","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana J-LM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26(10):1602\u201308. https:\/\/doi.org\/10.1038\/s41591-020-1005-2.","journal-title":"Nat Med"},{"key":"14233_CR14","doi-asserted-by":"publisher","unstructured":"Rosenthal PJ, Asua V, Bailey JA, Conrad MD, Ishengoma DS, Kamya MR, et al. The emergence of artemisinin partial resistance in Africa: How do we respond? The Lancet Infect Dis. 2024;24(9):e591\u2013600. https:\/\/doi.org\/10.1016\/S1473-3099(24)00141-5.","DOI":"10.1016\/S1473-3099(24)00141-5"},{"issue":"6","key":"14233_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41579-024-01008-2","volume":"22","author":"PJ Rosenthal","year":"2024","unstructured":"Rosenthal PJ, Asua V, Conrad MD. Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa. Nat Rev Microbiol. 2024;22(6):373\u201384. https:\/\/doi.org\/10.1038\/s41579-024-01008-2.","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"14233_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1473-3099(16)30409-1","volume":"17","author":"R Amato","year":"2017","unstructured":"Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, et al. Genetic markers associated with dihydroartemisinin\u2013piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype\u2013phenotype association study. The Lancet Infect Dis. 2017;17(2):164\u201373. https:\/\/doi.org\/10.1016\/S1473-3099(16)30409-1.","journal-title":"The Lancet Infect Dis"},{"issue":"2","key":"14233_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","volume":"17","author":"B Witkowski","year":"2017","unstructured":"Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype\u2013genotype association study. The Lancet Infect Dis. 2017;17(2):174\u201383. https:\/\/doi.org\/10.1016\/S1473-3099(16)30415-7.","journal-title":"The Lancet Infect Dis"},{"issue":"7481","key":"14233_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505(7481):50\u201355. https:\/\/doi.org\/10.1038\/nature12876.","journal-title":"Nature"},{"issue":"5","key":"14233_CR19","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1086\/596738","volume":"199","author":"C Sisowath","year":"2009","unstructured":"Sisowath C, Petersen I, Veiga MI, M\u00e5rtensson A, Premji Z, Bj\u00f6rkman A, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with Artemether-Lumefantrine in Africa. The J Infect Dis. 2009;199(5):750\u201357. https:\/\/doi.org\/10.1086\/596738.","journal-title":"The J Infect Dis"},{"issue":"6","key":"14233_CR20","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1086\/427997","volume":"191","author":"C Sisowath","year":"2005","unstructured":"Sisowath C, Str\u00f6mberg J, M\u00e5rtensson A, Msellem M, Obondo C, Bj\u00f6rkman A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by Artemether-Lumefantrine (Coartem). The J Infect Dis. 2005;191(6):1014\u201317. https:\/\/doi.org\/10.1086\/427997.","journal-title":"The J Infect Dis"},{"issue":"6220","key":"14233_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.1260867","volume":"347","author":"J Straimer","year":"2015","unstructured":"Straimer J, Gn\u00e4dig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015;347(6220):428\u201331. https:\/\/doi.org\/10.1126\/science.1260867.","journal-title":"Science"},{"key":"14233_CR22","doi-asserted-by":"publisher","unstructured":"Veiga MI, Ferreira PE, J\u00f6rnhagen L, Malmberg M, Kone A, Schmidt BA, et al. Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with Major ACT antimalarial drug resistance. PLoS ONE. 2011;6(5):e20212. https:\/\/doi.org\/10.1371\/journal.pone.0020212.","DOI":"10.1371\/journal.pone.0020212"},{"issue":"1","key":"14233_CR23","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1038\/ncomms11553","volume":"7","author":"MI Veiga","year":"2016","unstructured":"Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gn\u00e4dig N, Uhlemann A-C, et al. Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nat Commun. 2016;7(1):11553. https:\/\/doi.org\/10.1038\/ncomms11553.","journal-title":"Nat Commun"},{"issue":"1","key":"14233_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/s0031182099006022","volume":"121","author":"MT Duraisingh","year":"2000","unstructured":"Duraisingh MT, von Seidlein LV, Jepson A, Jones P, Sambou I, Pinder M, et al. Linkage disequilibrium between two chromosomally distinct loci associated with increased resistance to chloroquine in Plasmodium falciparum. Parasitology. 2000;121(1):1\u20137. https:\/\/doi.org\/10.1017\/s0031182099006022.","journal-title":"Parasitology"},{"issue":"1","key":"14233_CR25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12936-015-0791-3","volume":"14","author":"SJ Reiling","year":"2015","unstructured":"Reiling SJ, Rohrbach P. Monitoring PfMDR1 transport in Plasmodium falciparum. Malar J. 2015;14(1):270. https:\/\/doi.org\/10.1186\/s12936-015-0791-3.","journal-title":"Malar J"},{"issue":"6772","key":"14233_CR26","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/35002615","volume":"403","author":"MB Reed","year":"2000","unstructured":"Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature. 2000;403(6772):906\u201309. https:\/\/doi.org\/10.1038\/35002615.","journal-title":"Nature"},{"issue":"1\u20133","key":"14233_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1008080911522","volume":"27","author":"I Bosch","year":"1998","unstructured":"Bosch I, Croop JM. P-glycoprotein structure and evolutionary homologies. Cytotechnology. 1998;27(1\u20133):1\u201330. https:\/\/doi.org\/10.1023\/A:1008080911522.","journal-title":"Cytotechnology"},{"issue":"13","key":"14233_CR28","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1038\/sj.emboj.7601203","volume":"25","author":"P Rohrbach","year":"2006","unstructured":"Rohrbach P, Sanchez CP, Hayton K, Friedrich O, Patel J, Sidhu ABS, et al. Genetic linkage of pfmdr1 with food vacuolar solute import in Plasmodium falciparum. Embo J. 2006;25(13):3000\u201311. https:\/\/doi.org\/10.1038\/sj.emboj.7601203.","journal-title":"Embo J"},{"issue":"4","key":"14233_CR29","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1086\/507115","volume":"194","author":"ABS Sidhu","year":"2006","unstructured":"Sidhu ABS, Uhlemann A-C, Valderramos SG, Valderramos J-C, Krishna S, Fidock DA. Decreasing pfmdr1 Copy Number in Plasmodium falciparum Malaria Heightens Susceptibility to Mefloquine, Lumefantrine, Halofantrine, Quinine, and Artemisinin. The J Infect Dis. 2006;194(4):528\u201335. https:\/\/doi.org\/10.1086\/507115.","journal-title":"The J Infect Dis"},{"issue":"8","key":"14233_CR30","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1128\/AAC.47.8.2418-2423.2003","volume":"47","author":"AL Pickard","year":"2003","unstructured":"Pickard AL, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, Zalewski C, et al. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother. 2003;47(8):2418\u201323. https:\/\/doi.org\/10.1128\/AAC.47.8.2418-2423.2003.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9432","key":"14233_CR31","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0140-6736(04)16767-6","volume":"364","author":"RN Price","year":"2004","unstructured":"Price RN, Uhlemann A-C, Brockman A, McGready R, Ashley E, Phaipun L, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004;364(9432):438\u201347. https:\/\/doi.org\/10.1016\/S0140-6736(04)16767-6.","journal-title":"Lancet"},{"issue":"4","key":"14233_CR32","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1365-2958.2005.04729.x","volume":"57","author":"ABS Sidhu","year":"2005","unstructured":"Sidhu ABS, Valderramos SG, Fidock DA. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol. 2005;57(4):913\u201326. https:\/\/doi.org\/10.1111\/j.1365-2958.2005.04729.x.","journal-title":"Mol Microbiol"},{"issue":"6","key":"14233_CR33","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/14787210.2017.1313703","volume":"15","author":"JP Gil","year":"2017","unstructured":"Gil JP, Krishna S. pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies. Expert Rev Anti Infect Ther. 2017;15(6):527\u201343. https:\/\/doi.org\/10.1080\/14787210.2017.1313703.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"3","key":"14233_CR34","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1128\/AAC.00875-06","volume":"51","author":"GS Humphreys","year":"2007","unstructured":"Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJM, Mutabingwa TK, Sutherland CJ, et al. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother. 2007;51(3):991\u201397. https:\/\/doi.org\/10.1128\/AAC.00875-06.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"14233_CR35","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4269\/ajtmh.14-0031","volume":"91","author":"M Venkatesan","year":"2014","unstructured":"Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine Resistance transporter and multidrug Resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91(4):833\u201343. https:\/\/doi.org\/10.4269\/ajtmh.14-0031.","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"14233_CR36","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S1097-2765(05)00077-8","volume":"6","author":"DA Fidock","year":"2000","unstructured":"Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000;6(4):861\u201371. https:\/\/doi.org\/10.1016\/S1097-2765(05)00077-8.","journal-title":"Mol Cell"},{"issue":"5948","key":"14233_CR37","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1126\/science.1175667","volume":"325","author":"RE Martin","year":"2009","unstructured":"Martin RE, Marchetti RV, Cowan AI, Howitt SM, Br\u00f6er S, Kirk K. Chloroquine transport via the malaria Parasite\u2019s chloroquine resistance transporter. Science. 2009;325(5948):1680\u201382. https:\/\/doi.org\/10.1126\/science.1175667.","journal-title":"Science"},{"issue":"1","key":"14233_CR38","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1038\/s41467-020-17781-6","volume":"11","author":"SH Shafik","year":"2020","unstructured":"Shafik SH, Cobbold SA, Barkat K, Richards SN, Lancaster NS, Llin\u00e1s M, et al. The natural function of the malaria parasite\u2019s chloroquine resistance transporter. Nat Commun. 2020;11(1):3922. https:\/\/doi.org\/10.1038\/s41467-020-17781-6.","journal-title":"Nat Commun"},{"issue":"4","key":"14233_CR39","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/infdis\/jix334","volume":"216","author":"S Agrawal","year":"2017","unstructured":"Agrawal S, Moser KA, Morton L, Cummings MP, Parihar A, Dwivedi A, et al. Association of a novel mutation in the Plasmodium falciparum chloroquine resistance transporter with decreased piperaquine sensitivity. The J Infect Dis. 2017;216(4):468\u201376. https:\/\/doi.org\/10.1093\/infdis\/jix334.","journal-title":"The J Infect Dis"},{"issue":"5591","key":"14233_CR40","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1126\/science.1074045","volume":"298","author":"ABS Sidhu","year":"2002","unstructured":"Sidhu ABS, Verdier-Pinard D, Fidock DA. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science. 2002;298(5591):210\u201313. https:\/\/doi.org\/10.1126\/science.1074045.","journal-title":"Science"},{"key":"14233_CR41","doi-asserted-by":"publisher","unstructured":"Silva M, Malmberg M, Otienoburu SD, Bj\u00f6rkman A, Ngasala B, M\u00e5rtensson A, et al. Plasmodium falciparum drug resistance genes pfmdr1 and pfcrt in vivo Co-expression during artemether-lumefantrine therapy. Front Pharmacol. 2022, 13;13. https:\/\/doi.org\/10.3389\/fphar.2022.868723.","DOI":"10.3389\/fphar.2022.868723"},{"issue":"1","key":"14233_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4103\/2229-5070.175081","volume":"6","author":"HA Antony","year":"2016","unstructured":"Antony HA, Parija SC. Antimalarial drug resistance: an overview. Trop Parasitol. 2016;6(1):30\u201341. https:\/\/doi.org\/10.4103\/2229-5070.175081.","journal-title":"Trop Parasitol"},{"issue":"2","key":"14233_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1006\/expr.2001.4618","volume":"98","author":"S Thaithong","year":"2001","unstructured":"Thaithong S, Ranford-Cartwright LC, Siripoon N, Harnyuttanakorn P, Kanchanakhan NS, Seugorn A, et al. Plasmodium falciparum: gene mutations and amplification of Dihydrofolate reductase genes in parasites grown in vitro in presence of Pyrimethamine. Exp Parasitol. 2001;98(2):59\u201370. https:\/\/doi.org\/10.1006\/expr.2001.4618.","journal-title":"Exp Parasitol"},{"issue":"18","key":"14233_CR44","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1111\/j.1742-4658.2007.05999.x","volume":"274","author":"JE Hyde","year":"2007","unstructured":"Hyde JE. Drug-resistant malaria \u2212 an insight. The FEBS J. 2007;274(18):4688\u201398. https:\/\/doi.org\/10.1111\/j.1742-4658.2007.05999.x.","journal-title":"The FEBS J"},{"issue":"11","key":"14233_CR45","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.febslet.2011.04.042","volume":"585","author":"I Petersen","year":"2011","unstructured":"Petersen I, Eastman R, Lanzer M. Drug-resistant malaria: molecular mechanisms and implications for public health. FEBS Lett. 2011;585(11):1551\u201362. https:\/\/doi.org\/10.1016\/j.febslet.2011.04.042.","journal-title":"FEBS Lett"},{"key":"14233_CR46","doi-asserted-by":"publisher","unstructured":"Walker A, Ross A, Nsanzabana C. Changes in the prevalence of antimalarial partner drug resistance markers and policy in 6 sub-Saharan African countries from 2000 to 2021: a systematic review. Open Forum Infect Dis. 2025;12(9):ofaf508. https:\/\/doi.org\/10.1093\/ofid\/ofaf508.","DOI":"10.1093\/ofid\/ofaf508"},{"issue":"2","key":"14233_CR47","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/pathogens15020179","volume":"15","author":"F Habarugira","year":"2026","unstructured":"Habarugira F, Batamuriza J, Ndahimana R, Minega JN, Dieng MM, Mutsaka-Makuvaza MJ, et al. The global landscape of Plasmodium falciparum drug resistance markers, 2005\u20132025: a systematic review and meta-analysis. Pathogens. 2026;15(2):179. https:\/\/doi.org\/10.3390\/pathogens15020179.","journal-title":"Pathogens"},{"key":"14233_CR48","doi-asserted-by":"publisher","first-page":"108033","DOI":"10.1016\/j.ijid.2025.108033","volume":"159","author":"P Gashema","year":"2025","unstructured":"Gashema P, Kagame J, Iradukunda PG, Siddig EE, Tessema SK, Tegegne MA, et al. Mapping Plasmodium falciparum mutations in Africa: a critical review of emerging drug resistance and implications for malaria control. Int J Infect Dis. 2025;159:108033. https:\/\/doi.org\/10.1016\/j.ijid.2025.108033.","journal-title":"Int J Infect Dis"},{"key":"14233_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jgar.2024.12.019","volume":"41","author":"W Abebe","year":"2025","unstructured":"Abebe W, Mekuanint A, Asmare Z, Woldesenbet D, Mihret Y, Setegn A, et al. Prevalence of molecular markers of chloroquine resistance in malaria parasites in East Africa: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2025;41:117\u201337. https:\/\/doi.org\/10.1016\/j.jgar.2024.12.019.","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"14233_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. https:\/\/doi.org\/10.1186\/2046-4053-4-1.","journal-title":"Syst Rev"},{"issue":"1","key":"14233_CR51","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"14233_CR52","unstructured":"ACT Efficacy Africa. n.d. https:\/\/app.covidence.org\/reviews\/359664. March 13, 2025."},{"issue":"3","key":"14233_CR53","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","volume":"13","author":"Z Munn","year":"2015","unstructured":"Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. JBI Evid Implement. 2015;13(3):147. https:\/\/doi.org\/10.1097\/XEB.0000000000000054.","journal-title":"JBI Evid Implement"},{"key":"14233_CR54","doi-asserted-by":"publisher","unstructured":"Sedgwick P. Meta-analyses: heterogeneity and subgroup analysis. BMJ. 2013;346:f4040. https:\/\/doi.org\/10.1136\/bmj.f4040.","DOI":"10.1136\/bmj.f4040"},{"issue":"1","key":"14233_CR55","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12936-021-03760-9","volume":"20","author":"Y Diarra","year":"2021","unstructured":"Diarra Y, Kon\u00e9 O, Sangar\u00e9 L, Doumbia L, Haidara DBB, Diallo M, et al. Therapeutic efficacy of artemether\u2013lumefantrine and artesunate\u2013amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 2015\u20132016. Malar J. 2021;20(1):235. https:\/\/doi.org\/10.1186\/s12936-021-03760-9.","journal-title":"Malar J"},{"issue":"1","key":"14233_CR56","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12936-021-03585-6","volume":"20","author":"A Gansan\u00e9","year":"2021","unstructured":"Gansan\u00e9 A, Moriarty LF, M\u00e9nard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017\u20132018. Malar J. 2021;20(1):48. https:\/\/doi.org\/10.1186\/s12936-021-03585-6.","journal-title":"Malar J"},{"key":"14233_CR57","doi-asserted-by":"publisher","unstructured":"Falade CO, Orimadegun AE, Olusola FI, Michael OS, Anjorin OE, Funwei R, et al. Efficacy and safety of pyronaridine\u2013artesunate versus artemether\u2013lumefantrine in the treatment of acute uncomplicated malaria in children in South-West Nigeria: an open-labelled randomized controlled trial. Malar J. 2023, 22;22(1). https:\/\/doi.org\/10.1186\/s12936-023-04574-7.","DOI":"10.1186\/s12936-023-04574-7"},{"issue":"1","key":"14233_CR58","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s12936-025-05679-x","volume":"24","author":"IM Laminou","year":"2025","unstructured":"Laminou IM, Kabirou SM, Arzika II, Yahaya A, Ahmed J, Deme AB, et al. Therapeutic efficacy of artemether-lumefantrine and molecular markers of antimalarial resistance in Niger, 2022. Malar J. 2025;24(1):448. https:\/\/doi.org\/10.1186\/s12936-025-05679-x.","journal-title":"Malar J"},{"issue":"4","key":"14233_CR59","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.4269\/ajtmh.21-0214","volume":"105","author":"LF Moriarty","year":"2021","unstructured":"Moriarty LF, Nkoli PM, Likwela JL, Mulopo PM, Sompwe EM, Rika JM, et al. Therapeutic efficacy of artemisinin-based combination therapies in democratic republic of the Congo and investigation of molecular markers of antimalarial resistance. Am J Trop Med Hyg. 2021;105(4):1067\u201375. https:\/\/doi.org\/10.4269\/ajtmh.21-0214.","journal-title":"Am J Trop Med Hyg"},{"key":"14233_CR60","doi-asserted-by":"publisher","unstructured":"Dimbu PR, Horth R, C\u00e2ndido ALM, Ferreira CM, Caquece F, Garcia LEA, et al. Continued Low efficacy of Artemether-Lumefantrine in Angola in 2019. Antimicrob Agents Chemother. 2021;65(2):e01949\u201320. https:\/\/doi.org\/10.1128\/AAC.01949-20.","DOI":"10.1128\/AAC.01949-20"},{"key":"14233_CR61","doi-asserted-by":"publisher","unstructured":"Westercamp N, Owidhi M, Otieno K, Chebore W, Buff AM, Desai M, et al. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria among children in Western Kenya, 2016 to 2017. Antimicrob Agents Chemother. 2022;66(9):e0020722. https:\/\/doi.org\/10.1128\/aac.00207-22.","DOI":"10.1128\/aac.00207-22"},{"issue":"1","key":"14233_CR62","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12936-021-04021-5","volume":"20","author":"C Ebong","year":"2021","unstructured":"Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, et al. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Malar J. 2021;20(1):484. https:\/\/doi.org\/10.1186\/s12936-021-04021-5.","journal-title":"Malar J"},{"key":"14233_CR63","doi-asserted-by":"publisher","unstructured":"Balmer AJ, White NF, \u00dcnl\u00fc ES, Lee C, Pearson RD, Almagro-Garcia J, et al. Understanding the global rise of artemisinin resistance: insights from over 100, 000 Plasmodium falciparum samples. eLife. 2025;14:e105544. https:\/\/doi.org\/10.7554\/eLife.105544.","DOI":"10.7554\/eLife.105544"},{"key":"14233_CR64","unstructured":"Malaria Threat Map. n.d. https:\/\/apps.who.int\/malaria\/maps\/threats\/#\/maps?theme=treatment%26mapType=treatment%3A2%26bounds=%5B%5B-287.076554610606%2C-68.93921582505943%5D%2C%5B300.54507561427863%2C84.37124834597381%5D%5D%26insecticideClass=PYRETHROIDS%26insecticideTypes=%26assayTypes=%26synergistTypes=%26species=%26vectorSpecies=%26surveyTypes=%26plasmodiumSpecies=P._FALCIPARUM%26drugs=DRUG_AL%26mmType=4%26excludeLowerPatients=false%26excludeLowerSamples=false%26endemicity=false%26storyMode=false%26storyModeStep=0%26years=1993%2C2026. March 2, 2026."},{"key":"14233_CR65","unstructured":"Artemisinin Molecular Surveyor. n.d. https:\/\/visualizer.iddo.org\/map\/k13. March 2, 2026."},{"issue":"13","key":"14233_CR66","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2210956","volume":"389","author":"S Mihreteab","year":"2023","unstructured":"Mihreteab S, Platon L, Berhane A, Stokes BH, Warsame M, Campagne P, et al. Increasing prevalence of artemisinin-resistant HRP2-negative malaria in Eritrea. N Engl J Med. 2023;389(13):1191\u2013202. https:\/\/doi.org\/10.1056\/NEJMoa2210956.","journal-title":"N Engl J Med"},{"issue":"8","key":"14233_CR67","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. The Lancet Infect Dis. 2021;21(8):1120\u201328. https:\/\/doi.org\/10.1016\/S1473-3099(21)00142-0.","journal-title":"The Lancet Infect Dis"},{"issue":"13","key":"14233_CR68","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385(13):1163\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2101746.","journal-title":"N Engl J Med"},{"key":"14233_CR69","doi-asserted-by":"publisher","unstructured":"Angwe MK, Mwebaza N, Nsobya SL, Vudriko P, Dralabu S, Omali D, et al. Day 3 parasitemia and Plasmodium falciparum Kelch 13 mutations among uncomplicated malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda. PLoS ONE. 2024;19(6):e0305064. https:\/\/doi.org\/10.1371\/journal.pone.0305064.","DOI":"10.1371\/journal.pone.0305064"},{"issue":"11","key":"14233_CR70","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1473-3099(24)00362-1","volume":"24","author":"DS Ishengoma","year":"2024","unstructured":"Ishengoma DS, Mandara CI, Bakari C, Fola AA, Madebe RA, Seth MD, et al. Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. The Lancet Infect Dis. 2024;24(11):1225\u201333. https:\/\/doi.org\/10.1016\/S1473-3099(24)00362-1.","journal-title":"The Lancet Infect Dis"},{"key":"14233_CR71","doi-asserted-by":"publisher","unstructured":"Zeleke AJ, Fola AA, Tollefson GA, Niar\u00e9 K, Leonetti A, Taropawala O, et al. High prevalence and emerging positive association of kelch13 R622I and HRP2-based RDT negativity in Plasmodium falciparum in northern Ethiopia. PLoS Pathog. 2025;21(12):e1013771. https:\/\/doi.org\/10.1371\/journal.ppat.1013771.","DOI":"10.1371\/journal.ppat.1013771"},{"issue":"1","key":"14233_CR72","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s43856-025-01008-0","volume":"5","author":"BG Brhane","year":"2025","unstructured":"Brhane BG, Fola AA, Nigussie H, Leonetti A, Kassa M, Hailgiorgis H, et al. Rising prevalence of Plasmodium falciparum Artemisinin partial resistance mutations in Ethiopia. Commun Med. 2025;5(1):297. https:\/\/doi.org\/10.1038\/s43856-025-01008-0.","journal-title":"Commun Med"},{"key":"14233_CR73","doi-asserted-by":"publisher","unstructured":"Eloff L, Aranda-D\u00edaz A, Routledge I, Wesolowski A, Chisenga M, Mangena B, et al. High prevalence of molecular markers associated with Artemisinin, sulfadoxine, and pyrimethamine resistance in northern Namibia. Am J Trop Med Hyg. 2025;1. https:\/\/doi.org\/10.4269\/ajtmh.24-0870.","DOI":"10.4269\/ajtmh.24-0870"},{"key":"14233_CR74","doi-asserted-by":"publisher","unstructured":"L\u2019Episcopia M, Talha AA, Nour BYM, Sana IMA, Caspar E, Thiebaut L, et al. High prevalence of artemisinin-resistant Plasmodium falciparum, Southeastern Sudan. Emerg Infect Dis. 2025;31(6). https:\/\/doi.org\/10.3201\/eid3106.241810.","DOI":"10.3201\/eid3106.241810"},{"issue":"4","key":"14233_CR75","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/infdis\/jiaf188","volume":"232","author":"AC Martin","year":"2025","unstructured":"Martin AC, Sadler JM, Simkin A, Musonda M, Katowa B, Matoba J, et al. Emergence and rising prevalence of artemisinin partial resistance marker Kelch13 P441L in a low malaria transmission setting in Southern Zambia. medRxiv, 2025: 2025.01.02.24319706. The J Infect Dis. 2025;232(4):918\u201322. https:\/\/doi.org\/10.1093\/infdis\/jiaf188.","journal-title":"The J Infect Dis"},{"issue":"1","key":"14233_CR76","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/s12936-020-03506-z","volume":"19","author":"A Adamu","year":"2020","unstructured":"Adamu A, Jada MS, Haruna HMS, Yakubu BO, Ibrahim MA, Balogun EO, et al. Plasmodium falciparum multidrug resistance gene-1 polymorphisms in Northern Nigeria: implications for the continued use of artemether-lumefantrine in the region. Malar J. 2020;19(1):439. https:\/\/doi.org\/10.1186\/s12936-020-03506-z.","journal-title":"Malar J"},{"issue":"7","key":"14233_CR77","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/infdis\/jir486","volume":"204","author":"FN Baliraine","year":"2011","unstructured":"Baliraine FN, Rosenthal PJ. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. The J Infect Dis. 2011;204(7):1120\u201324. https:\/\/doi.org\/10.1093\/infdis\/jir486.","journal-title":"The J Infect Dis"},{"issue":"10","key":"14233_CR78","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.pt.2013.08.002","volume":"29","author":"I Naidoo","year":"2013","unstructured":"Naidoo I, Roper C. Mapping \u2018partially resistant\u2019, \u2018fully resistant\u2019, and \u2018super resistant\u2019 malaria. Trends Parasitol. 2013;29(10):505\u201315. https:\/\/doi.org\/10.1016\/j.pt.2013.08.002.","journal-title":"Trends Parasitol"},{"issue":"7","key":"14233_CR79","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/00034980120103234","volume":"95","author":"SA Omar","year":"2001","unstructured":"Omar SA, Adagu IS, Gump DW, Ndaru NP, Warhurst DC. Plasmodium falciparum in Kenya: high prevalence of drug-resistance-associated polymorphisms in hospital admissions with severe malaria in an epidemic area. Ann Trop Med Parasitol. 2001;95(7):661\u201369. https:\/\/doi.org\/10.1080\/00034980120103234.","journal-title":"Ann Trop Med Parasitol"},{"issue":"3","key":"14233_CR80","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1086\/338566","volume":"185","author":"JG Kublin","year":"2002","unstructured":"Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. The J Infect Dis. 2002;185(3):380\u201388. https:\/\/doi.org\/10.1086\/338566.","journal-title":"The J Infect Dis"},{"issue":"3","key":"14233_CR81","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/jac\/dkac432","volume":"78","author":"O Cohen","year":"2023","unstructured":"Cohen O, Guemas E, Menard S, Tsague Kenfack M, Talom Ngassa C, Iriart X, et al. Effect of sulfadoxine-pyrimethamine chemoprophylaxis in pregnant women on selection of the new P. falciparum dhps quintuple mutant carrying the I431V mutation. The J Antimicrob Chemother. 2023;78(3):665\u201368. https:\/\/doi.org\/10.1093\/jac\/dkac432.","journal-title":"The J Antimicrob Chemother"},{"issue":"8","key":"14233_CR82","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1172\/JCI21682","volume":"113","author":"NJ White","year":"2004","unstructured":"White NJ. Antimalarial drug resistance. J Clin Invest. 2004;113(8):1084\u201392. https:\/\/doi.org\/10.1172\/JCI21682.","journal-title":"J Clin Invest"},{"issue":"1\u20132","key":"14233_CR83","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.drup.2005.03.003","volume":"8","author":"IM Hastings","year":"2005","unstructured":"Hastings IM, Donnelly MJ. The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance. Drug Resist Updat. 2005;8(1\u20132):43\u201350. https:\/\/doi.org\/10.1016\/j.drup.2005.03.003.","journal-title":"Drug Resist Updat"},{"issue":"6","key":"14233_CR84","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/mmi.12349","volume":"89","author":"PJ Rosenthal","year":"2013","unstructured":"Rosenthal PJ. The interplay between drug resistance and fitness in malaria parasites. Mol Microbiol. 2013;89(6):1025\u201338. https:\/\/doi.org\/10.1111\/mmi.12349.","journal-title":"Mol Microbiol"},{"issue":"1","key":"14233_CR85","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12936-025-05286-w","volume":"24","author":"X Segovia","year":"2025","unstructured":"Segovia X, Srivastava B, Serrato-Arroyo S, Guerrero A, Huijben S. Assessing fitness costs in malaria parasites: a comprehensive review and implications for drug resistance management. Malar J. 2025;24(1):65. https:\/\/doi.org\/10.1186\/s12936-025-05286-w.","journal-title":"Malar J"},{"issue":"10","key":"14233_CR86","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.pt.2022.07.006","volume":"38","author":"CE Oke","year":"2022","unstructured":"Oke CE, Ingham VA, Walling CA, Reece SE. Vector control: agents of selection on malaria parasites? Trends Parasitol. 2022;38(10):890\u2013903. https:\/\/doi.org\/10.1016\/j.pt.2022.07.006.","journal-title":"Trends Parasitol"},{"key":"14233_CR87","doi-asserted-by":"publisher","unstructured":"Alout H, Ndam NT, Sandeu MM, Dj\u00e9gbe I, Chandre F, Dabir\u00e9 RK, et al. Insecticide resistance alleles affect vector competence of anopheles gambiae s.s. For Plasmodium falciparum field isolates. PLoS ONE. 2013;8(5):e63849. https:\/\/doi.org\/10.1371\/journal.pone.0063849.","DOI":"10.1371\/journal.pone.0063849"},{"issue":"1","key":"14233_CR88","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41598-025-86409-w","volume":"15","author":"PA Kweyamba","year":"2025","unstructured":"Kweyamba PA, Hofer LM, Kibondo UA, Mwanga RY, Sayi RM, Matwewe F, et al. Contrasting vector competence of three main East African Anopheles malaria vector mosquitoes for Plasmodium falciparum. Sci Rep. 2025;15(1):2286. https:\/\/doi.org\/10.1038\/s41598-025-86409-w.","journal-title":"Sci Rep"},{"key":"14233_CR89","doi-asserted-by":"publisher","unstructured":"Laurent B, Brandy. Mosquito vector diversity and malaria transmission. Front Malar. 2025, 3;3. https:\/\/doi.org\/10.3389\/fmala.2025.1600850.","DOI":"10.3389\/fmala.2025.1600850"},{"key":"14233_CR90","doi-asserted-by":"publisher","unstructured":"Artzy-Randrup Y, Alonso D, Pascual M. Transmission intensity and drug resistance in malaria population dynamics: implications for climate change. PLoS ONE. 2010;5(10):e13588. https:\/\/doi.org\/10.1371\/journal.pone.0013588.","DOI":"10.1371\/journal.pone.0013588"},{"key":"14233_CR91","doi-asserted-by":"crossref","unstructured":"Talisuna AO, Okello PE, Erhart A, Coosemans M, D\u2019Alessandro U. Intensity of malaria transmission and the spread of Plasmodium falciparum-resistant malaria: a review of epidemiologic Field evidence. Defin. Defeating intolerable Burd. Malar. III Prog. Perspect. Am. J Trop Med Hyg Vol. 776. American Society of Tropical Medicine and Hygiene; 2007.","DOI":"10.4269\/ajtmh.77.6.suppl.170"},{"issue":"3","key":"14233_CR92","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.actatropica.2005.04.003","volume":"94","author":"IM Hastings","year":"2005","unstructured":"Hastings IM, Watkins WM. Intensity of malaria transmission and the evolution of drug resistance. Acta Trop. 2005;94(3):218\u201329. https:\/\/doi.org\/10.1016\/j.actatropica.2005.04.003.","journal-title":"Acta Trop"},{"key":"14233_CR93","doi-asserted-by":"publisher","unstructured":"Bushman M, Antia R, Udhayakumar V, de JC. Within-host competition can delay evolution of drug resistance in malaria. PLoS Biol. 2018;16(8):e2005712. https:\/\/doi.org\/10.1371\/journal.pbio.2005712.","DOI":"10.1371\/journal.pbio.2005712"},{"key":"14233_CR94","doi-asserted-by":"publisher","unstructured":"Whitlock AOB, Juliano JJ, Mideo N. Immune selection suppresses the emergence of drug resistance in malaria parasites but facilitates its spread. PLoS Comput Biol. 2021;17(7):e1008577. https:\/\/doi.org\/10.1371\/journal.pcbi.1008577.","DOI":"10.1371\/journal.pcbi.1008577"},{"issue":"1","key":"14233_CR95","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41467-024-45547-x","volume":"15","author":"EZ Li","year":"2024","unstructured":"Li EZ, Nguyen TD, Tran T-A, Zupko RJ, Boni MF. Assessing emergence risk of double-resistant and triple-resistant genotypes of Plasmodium falciparum. Nat Commun. 2024;15(1):1390. https:\/\/doi.org\/10.1038\/s41467-024-45547-x.","journal-title":"Nat Commun"},{"key":"14233_CR96","doi-asserted-by":"publisher","unstructured":"Tran KT, Nguyen TD, Weissman DB, Li EZ, Mok S, Small-Saunders JL, et al. Effects of recombination on multi-drug resistance evolution in Plasmodium falciparum malaria. PLoS Comput Biol. 2025;21(8):e1013401. https:\/\/doi.org\/10.1371\/journal.pcbi.1013401.","DOI":"10.1371\/journal.pcbi.1013401"},{"issue":"5","key":"14233_CR97","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S1473-3099(18)30732-1","volume":"19","author":"AM van Eijk","year":"2019","unstructured":"van Eijk AM, Larsen DA, Kayentao K, Koshy G, Slaughter DEC, Roper C, et al. Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis. The Lancet Infect Dis. 2019;19(5):546\u201356. https:\/\/doi.org\/10.1016\/S1473-3099(18)30732-1.","journal-title":"The Lancet Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14233-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14233-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14233-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:00:44Z","timestamp":1788523244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-14233-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14233"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-14233-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1605"}}